Profile: Ardelyx Inc (ARDX.A)
7 May 2019
Ardelyx, Inc., incorporated on October 18, 2007, is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. The Company operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.
As of December 31, 2016, the Company's cardiorenal portfolio included two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. In addition to its two-phase III product candidates, the Company has two programs that are in research phase. Tenapanor is a minimally-systemic small molecule that acts locally in the GI tract to inhibit the sodium transporter sodium-hydrogen exchanger 3 (NHE3) and reduces sodium uptake from the gut. RDX7675 is an oral, non-absorbed, potassium-binding polymer. The Company's RDX013 program discovers and evaluates orally-administered small molecule therapeutic candidates that modulate the transport of potassium in the GI tract. RDX011 is a program that focuses on the discovery and development of second-generation NHE3 inhibitors.
The Company's gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The Company is evaluating tenapanor in two Phase III clinical trials in patients with IBS-C, T3MPO-1 and T3MPO-2. RDX8940 is a minimally absorbed oral TGR5 agonist. The Company is evaluating the development of RDX8940 for the treatment of patients with non-alcoholic steatohepatitis (NASH). The Company's RDX023 program focuses on the discovery and development of gut-biased farnesoid X receptor, agonists for the treatment of GI and inflammatory diseases.
34175 Ardenwood Blvd
FREMONT CA 94555-3653